Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The CUG repeat RNA hairpin in the 3' untranslated region (UTR) of the Dystrophia Myotonica Protein Kinase (DMPK) mRNA is the primary pathogenic driver of Myotonic Dystrophy Type 1 (DM1) [PMID: 11719800]. In healthy individuals, the DMPK gene contains 5 to 35 CTG repeats; however, in DM1 patients, this sequence expands to hundreds or thousands of repeats [PMID: 1346552]. These expanded repeats are transcribed into mRNA that folds into stable, toxic hairpin structures which accumulate in the nucleus as foci [PMID: 10910351]. These RNA foci sequester key RNA-binding proteins, most notably the Muscleblind-like (MBNL) family, and lead to the upregulation of CUG-binding protein 1 (CUGBP1) [PMID: 17652133]. The resulting imbalance in these splicing factors causes widespread spliceopathy, where fetal isoforms of various proteins are incorrectly expressed in adult tissues, leading to the clinical manifestations of DM1 such as myotonia, muscle wasting, and cardiac conduction defects [PMID: 22958864]. Therapeutic strategies targeting this RNA include antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), and small molecules designed to either degrade the toxic mRNA or disrupt the interaction between the CUG repeats and sequestered proteins [PMID: 35115704].
Therapeutic agents target the CUG repeat expansion to either induce RNase H-mediated degradation of the toxic mRNA, utilize the RNA interference (RNAi) pathway for silencing, or sterically block the repeats to release sequestered Muscleblind-like (MBNL) proteins [PMID: 35115704, PMID: 22958864].
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Dystrophia myotonica protein kinase (DMPK) mRNA CUG repeat expansion (DMPK (CUG)n RNA).